{"id":"W2807386738","doi":"10.1002/pros.23662","title":"A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration‐resistant prostate cancer","year":2018,"lang":"en","type":"article","venue":"The Prostate","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"McMaster University","funders":"National Cancer Institute; Exelixis","keywords":"Medicine; Cabozantinib; Abiraterone acetate; Prostate cancer; Tolerability; Cohort; Internal medicine; Urology; Oncology; Cabazitaxel; Prednisone; Cancer; Adverse effect; Androgen deprivation therapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001547964,0.001769084,0.001919772,0.0007503654,0.0005071222,0.001008263,0.001006536,0.001212625,0.003937735],"category_scores_gemma":[0.001010437,0.0006994688,0.0009440238,0.0005557696,0.001155738,0.0008632512,0.0003696301,0.003396041,0.0007579658],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00111207,"about_ca_system_score_gemma":0.001733686,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001121498,"about_ca_topic_score_gemma":0.002798744,"domain_scores_codex":[0.9994532,0.0002831493,0.00002612286,0.00008330976,0.00005461102,0.00009960893],"domain_scores_gemma":[0.9992273,0.0001335918,0.0001724678,0.00006613172,0.00004269122,0.0003578771],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8160945,0.0798514,0.002136955,0.0004884165,0.000848949,0.0001975912,0.000248264,0.002233274,0.04400095,0.0002648542,0.002158414,0.05147641],"study_design_scores_gemma":[0.5829591,0.4082581,0.003507993,0.00001415294,0.0001989603,0.0001359553,0.00002528724,0.0007457621,0.002888082,0.0001372319,0.001110673,0.0000185997],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9958646,0.0008100421,0.0002667383,0.0003002914,0.00009586263,0.001219523,0.000317187,0.0001101595,0.001015657],"genre_scores_gemma":[0.9929925,0.0008667374,0.001307359,0.0004187361,0.0001788049,0.001430292,0.0007041044,0.0000240388,0.002077481],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003937735,"threshold_uncertainty_score":0.01317298,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1291539729666525,"score_gpt":0.434792639625811,"score_spread":0.3056386666591585,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}